Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2020-03-09 Disposition | 2020-03-18 09:52 am | N/A 2024-12-29 | Foamix Pharmaceuticals Ltd. | FOMX | STERN STANLEY Director | 128,587 | $0 | 0 (Direct) | View |
| 2020-03-09 Disposition | 2020-03-11 5:41 pm | N/A 2028-12-03 | Foamix Pharmaceuticals Ltd. | FOMX | Wiley Matthew T. Chief Commercial Officer | 310,439 | $0 | 0 (Direct) | View |
| 2020-03-09 Disposition | 2020-03-11 5:41 pm | N/A 2026-11-15 | Foamix Pharmaceuticals Ltd. | FOMX | Stuart Iain Chief Scientific Officer | 358,998 | $0 | 0 (Direct) | View |
| 2020-03-09 Disposition | 2020-03-11 5:40 pm | N/A 2025-06-22 | Foamix Pharmaceuticals Ltd. | FOMX | Schwartz Aharon Director | 270,086 | $0 | 0 (Direct) | View |
| 2020-03-09 Disposition | 2020-03-11 5:39 pm | N/A 2024-12-29 | Foamix Pharmaceuticals Ltd. | FOMX | KAZANCHYAN ANNA Director | 69,744 | $0 | 0 (Direct) | View |
| 2020-03-09 Disposition | 2020-03-11 5:39 pm | N/A 2024-12-29 | Foamix Pharmaceuticals Ltd. | FOMX | Hirsch Stanley Director | 453,277 | $0 | 59,016 (Direct) | View |
| 2020-03-09 Disposition | 2020-03-11 5:39 pm | N/A 2028-02-27 | Foamix Pharmaceuticals Ltd. | FOMX | Harsch Mutya CLO and General Counsel | 314,894 | $0 | 0 (Direct) | View |
| 2020-03-09 Disposition | 2020-03-11 5:38 pm | N/A 2024-03-31 | Foamix Pharmaceuticals Ltd. | FOMX | Hadar Ilan CFO & Country Manager | 923,224 | $0 | 0 (Direct) | View |
| 2020-03-09 Disposition | 2020-03-11 5:38 pm | N/A 2024-06-09 | Foamix Pharmaceuticals Ltd. | FOMX | Domzalski David CEO | 1,520,769 | $0 | 0 (Direct) | View |
| 2020-03-09 Disposition | 2020-03-11 5:37 pm | N/A N/A | Foamix Pharmaceuticals Ltd. | FOMX | Bruno Anthony D Director | 75,007 | $0 | 0 (Direct) | View |
| 2020-03-09 Disposition | 2020-03-11 5:37 pm | N/A 2024-12-29 | Foamix Pharmaceuticals Ltd. | FOMX | Bright Rex Director | 161,077 | $0 | 0 (Direct) | View |
| 2020-03-09 Disposition | 2020-03-11 5:36 pm | N/A 2029-05-16 | Foamix Pharmaceuticals Ltd. | FOMX | BARBARI SHARON SURREY Director | 49,412 | $0 | 0 (Direct) | View |
| 2020-03-02 Option Award | 2020-03-03 4:39 pm | N/A N/A | Foamix Pharmaceuticals Ltd. | FOMX | Wiley Matthew T. Chief Commercial Officer | 1,993 | $2.6775 | 114,074 (Direct) | View |
| 2020-03-02 Option Award | 2020-03-03 4:38 pm | N/A N/A | Foamix Pharmaceuticals Ltd. | FOMX | Harsch Mutya CLO and General Counsel | 1,761 | $2.6775 | 98,232 (Direct) | View |
| 2020-03-02 Option Award | 2020-03-03 4:38 pm | N/A N/A | Foamix Pharmaceuticals Ltd. | FOMX | Domzalski David CEO | 4,705 | $2.6775 | 324,028 (Direct) | View |
| 2020-02-27 Option Award | 2020-03-03 4:36 pm | N/A 2030-02-27 | Foamix Pharmaceuticals Ltd. | FOMX | STERN STANLEY Director | 26,883 | $0 | 55,078 (Direct) | View |
| 2020-02-27 Option Award | 2020-03-03 4:33 pm | N/A 2030-02-27 | Foamix Pharmaceuticals Ltd. | FOMX | Schwartz Aharon Director | 38,156 | $0 | 38,156 (Direct) | View |
| 2020-02-27 Option Award | 2020-03-03 4:32 pm | N/A N/A | Foamix Pharmaceuticals Ltd. | FOMX | KAZANCHYAN ANNA Director | 21,246 | $0 | 58,744 (Direct) | View |
| 2020-02-27 Option Award | 2020-03-03 4:32 pm | N/A N/A | Foamix Pharmaceuticals Ltd. | FOMX | Hirsch Stanley Director | 42,493 | $0 | 294,358 (Direct) | View |
| 2020-02-27 Option Award | 2020-03-03 4:31 pm | N/A N/A | Foamix Pharmaceuticals Ltd. | FOMX | Bruno Anthony D Director | 5,312 | $0 | 75,007 (Direct) | View |
| 2020-02-27 Option Award | 2020-03-03 4:31 pm | N/A 2030-02-27 | Foamix Pharmaceuticals Ltd. | FOMX | Bright Rex Director | 38,156 | $0 | 38,156 (Direct) | View |
| 2020-02-24 Option Award | 2020-02-24 6:39 pm | N/A 2030-02-24 | Foamix Pharmaceuticals Ltd. | FOMX | Wiley Matthew T. Chief Commercial Officer | 137,664 | $0 | 208,446 (Direct) | View |
| 2020-02-24 Option Award | 2020-02-24 6:39 pm | N/A 2030-02-24 | Foamix Pharmaceuticals Ltd. | FOMX | Stuart Iain Chief Scientific Officer | 137,664 | $0 | 200,001 (Direct) | View |
| 2020-02-24 Option Award | 2020-02-24 6:38 pm | N/A 2030-02-24 | Foamix Pharmaceuticals Ltd. | FOMX | Harsch Mutya CLO and General Counsel | 137,664 | $0 | 192,836 (Direct) | View |
| 2020-02-24 Option Award | 2020-02-24 6:38 pm | N/A 2030-02-24 | Foamix Pharmaceuticals Ltd. | FOMX | Hadar Ilan CFO & Country Manager | 137,664 | $0 | 226,943 (Direct) | View |
| 2020-02-24 Option Award | 2020-02-24 6:38 pm | N/A 2030-02-24 | Foamix Pharmaceuticals Ltd. | FOMX | Domzalski David CEO | 344,160 | $0 | 560,235 (Direct) | View |
| 2019-12-31 Tax Withholding | 2020-01-03 5:24 pm | N/A N/A | Foamix Pharmaceuticals Ltd. | FOMX | Wiley Matthew T. Chief Commercial Officer | 2,500 | $3.28 | 70,782 (Direct) | View |
| 2019-12-31 Tax Withholding | 2020-01-03 5:23 pm | N/A N/A | Foamix Pharmaceuticals Ltd. | FOMX | Stuart Iain Chief Scientific Officer | 514 | $3.28 | 62,337 (Direct) | View |
| 2019-12-31 Tax Withholding | 2020-01-03 5:23 pm | N/A N/A | Foamix Pharmaceuticals Ltd. | FOMX | Harsch Mutya CLO and General Counsel | 618 | $3.28 | 55,172 (Direct) | View |
| 2019-12-31 Tax Withholding | 2020-01-03 5:22 pm | N/A N/A | Foamix Pharmaceuticals Ltd. | FOMX | Domzalski David CEO | 2,751 | $3.28 | 216,075 (Direct) | View |
| 2019-11-29 Option Award | 2019-12-03 4:32 pm | N/A N/A | Foamix Pharmaceuticals Ltd. | FOMX | Domzalski David CEO | 9,842 | $2.159 | 218,826 (Direct) | View |
| 2019-11-29 Option Award | 2019-12-03 4:31 pm | N/A N/A | Foamix Pharmaceuticals Ltd. | FOMX | Wiley Matthew T. Chief Commercial Officer | 9,842 | $2.159 | 73,282 (Direct) | View |
| 2019-11-29 Option Award | 2019-12-03 4:30 pm | N/A N/A | Foamix Pharmaceuticals Ltd. | FOMX | Harsch Mutya CLO and General Counsel | 4,284 | $2.159 | 55,790 (Direct) | View |